Am J Obstet Gyneco:前哨淋巴结活检在子宫恶性肿瘤中的应用

2017-06-23 李卫华 彭澎 教授 协和妇产科文献月报

为了避免系统性淋巴结清扫的并发症,可以通过切除淋巴引流第一站的淋巴结,即前哨淋巴结活检,来判断内膜癌转移的风险。尽管前哨淋巴结活检能够降低系统淋巴结切除的合并症,但是其有效性和使用的广泛程度尚未得知。美国哥伦比亚大学以2011年-2015年切除子宫的的子宫体恶性肿瘤患者为研究对象,将其分为三组:淋巴结清扫组、前哨淋巴结活检组和无淋巴结评估组。用多因素分析模型分析临床、人口学特征和住院指标与前哨淋巴

为了避免系统性淋巴结清扫的并发症,可以通过切除淋巴引流第一站的淋巴结,即前哨淋巴结活检,来判断内膜癌转移的风险。尽管前哨淋巴结活检能够降低系统淋巴结切除的合并症,但是其有效性和使用的广泛程度尚未得知。


美国哥伦比亚大学以2011年-2015年切除子宫的的子宫体恶性肿瘤患者为研究对象,将其分为三组:淋巴结清扫组、前哨淋巴结活检组和无淋巴结评估组。用多因素分析模型分析临床、人口学特征和住院指标与前哨淋巴结活检之间的关系,并评估不同淋巴结评估患者之间的住院时长及花费。本研究纳入28362名患者,其中9327(32.9%)名患者未进行淋巴结评估,17669(62.3%)名患者进行了淋巴结清扫,1366(4.8%)名患者进行了前哨淋巴结的活检。开腹子宫切除的患者中前哨淋巴结的活检率为1.3%(95% CI 1.0-1.6%),腹腔镜下子宫切除的患者中前哨淋巴结的活检率为3.4%(95% CI 2.7-4.1%),而在机器人辅助下子宫切除的患者中前哨淋巴结的活检率为7.5%(95% CI 7.0-8.0%)。在多因素分析模型中,近年的手术中,前哨淋巴结的活检率增加。

与开腹子宫切除相比,腹腔镜下和机器人辅助的子宫切除更有可能进行前哨淋巴结的活检,其调整危险比分别为2.45(95% CI 1.89-3.18)和2.69(95% CI 2.19-3.30)。在创伤性最小的子宫切除的患者中,前哨淋巴结活检患者的住院时长及花费要低于行淋巴结清扫的患者。

研究结论为:自2011年至2015年,子宫内膜癌患者中前哨淋巴结的活检率增加,其在机器人辅助下的子宫切除患者中的应用增加更明显。

原始出处
Wright JD, Cham S, Chen L, et al. Utilization of sentinel lymph nodebiopsy for uterine cancer. Am J Obstet Gynecol. 2017;216(6):594 e1-594 e13.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2043974, encodeId=4ab920439e478, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 20 16:43:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664888, encodeId=95c116648884c, content=<a href='/topic/show?id=9bd2325e9f7' target=_blank style='color:#2F92EE;'>#前哨淋巴结活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32579, encryptionId=9bd2325e9f7, topicName=前哨淋巴结活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979a25868441, createdName=dlwang_26703135, createdTime=Wed Mar 07 12:43:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011308, encodeId=d27620113081b, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Apr 30 23:43:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278014, encodeId=ea6312e80148b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292988, encodeId=1aa412929885e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534832, encodeId=a3b0153483291, content=<a href='/topic/show?id=47ee325e539' target=_blank style='color:#2F92EE;'>#前哨淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32575, encryptionId=47ee325e539, topicName=前哨淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89e12549488, createdName=by2013, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214434, encodeId=e5c6214434af, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Jun 23 17:48:54 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2043974, encodeId=4ab920439e478, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 20 16:43:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664888, encodeId=95c116648884c, content=<a href='/topic/show?id=9bd2325e9f7' target=_blank style='color:#2F92EE;'>#前哨淋巴结活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32579, encryptionId=9bd2325e9f7, topicName=前哨淋巴结活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979a25868441, createdName=dlwang_26703135, createdTime=Wed Mar 07 12:43:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011308, encodeId=d27620113081b, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Apr 30 23:43:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278014, encodeId=ea6312e80148b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292988, encodeId=1aa412929885e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534832, encodeId=a3b0153483291, content=<a href='/topic/show?id=47ee325e539' target=_blank style='color:#2F92EE;'>#前哨淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32575, encryptionId=47ee325e539, topicName=前哨淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89e12549488, createdName=by2013, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214434, encodeId=e5c6214434af, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Jun 23 17:48:54 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2043974, encodeId=4ab920439e478, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 20 16:43:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664888, encodeId=95c116648884c, content=<a href='/topic/show?id=9bd2325e9f7' target=_blank style='color:#2F92EE;'>#前哨淋巴结活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32579, encryptionId=9bd2325e9f7, topicName=前哨淋巴结活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979a25868441, createdName=dlwang_26703135, createdTime=Wed Mar 07 12:43:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011308, encodeId=d27620113081b, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Apr 30 23:43:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278014, encodeId=ea6312e80148b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292988, encodeId=1aa412929885e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534832, encodeId=a3b0153483291, content=<a href='/topic/show?id=47ee325e539' target=_blank style='color:#2F92EE;'>#前哨淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32575, encryptionId=47ee325e539, topicName=前哨淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89e12549488, createdName=by2013, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214434, encodeId=e5c6214434af, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Jun 23 17:48:54 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2018-04-30 yhy100200
  4. [GetPortalCommentsPageByObjectIdResponse(id=2043974, encodeId=4ab920439e478, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 20 16:43:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664888, encodeId=95c116648884c, content=<a href='/topic/show?id=9bd2325e9f7' target=_blank style='color:#2F92EE;'>#前哨淋巴结活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32579, encryptionId=9bd2325e9f7, topicName=前哨淋巴结活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979a25868441, createdName=dlwang_26703135, createdTime=Wed Mar 07 12:43:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011308, encodeId=d27620113081b, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Apr 30 23:43:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278014, encodeId=ea6312e80148b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292988, encodeId=1aa412929885e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534832, encodeId=a3b0153483291, content=<a href='/topic/show?id=47ee325e539' target=_blank style='color:#2F92EE;'>#前哨淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32575, encryptionId=47ee325e539, topicName=前哨淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89e12549488, createdName=by2013, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214434, encodeId=e5c6214434af, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Jun 23 17:48:54 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2017-06-25 smlt2008
  5. [GetPortalCommentsPageByObjectIdResponse(id=2043974, encodeId=4ab920439e478, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 20 16:43:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664888, encodeId=95c116648884c, content=<a href='/topic/show?id=9bd2325e9f7' target=_blank style='color:#2F92EE;'>#前哨淋巴结活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32579, encryptionId=9bd2325e9f7, topicName=前哨淋巴结活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979a25868441, createdName=dlwang_26703135, createdTime=Wed Mar 07 12:43:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011308, encodeId=d27620113081b, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Apr 30 23:43:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278014, encodeId=ea6312e80148b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292988, encodeId=1aa412929885e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534832, encodeId=a3b0153483291, content=<a href='/topic/show?id=47ee325e539' target=_blank style='color:#2F92EE;'>#前哨淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32575, encryptionId=47ee325e539, topicName=前哨淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89e12549488, createdName=by2013, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214434, encodeId=e5c6214434af, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Jun 23 17:48:54 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2017-06-25 sodoo
  6. [GetPortalCommentsPageByObjectIdResponse(id=2043974, encodeId=4ab920439e478, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 20 16:43:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664888, encodeId=95c116648884c, content=<a href='/topic/show?id=9bd2325e9f7' target=_blank style='color:#2F92EE;'>#前哨淋巴结活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32579, encryptionId=9bd2325e9f7, topicName=前哨淋巴结活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979a25868441, createdName=dlwang_26703135, createdTime=Wed Mar 07 12:43:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011308, encodeId=d27620113081b, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Apr 30 23:43:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278014, encodeId=ea6312e80148b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292988, encodeId=1aa412929885e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534832, encodeId=a3b0153483291, content=<a href='/topic/show?id=47ee325e539' target=_blank style='color:#2F92EE;'>#前哨淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32575, encryptionId=47ee325e539, topicName=前哨淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89e12549488, createdName=by2013, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214434, encodeId=e5c6214434af, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Jun 23 17:48:54 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2043974, encodeId=4ab920439e478, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Aug 20 16:43:00 CST 2017, time=2017-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1664888, encodeId=95c116648884c, content=<a href='/topic/show?id=9bd2325e9f7' target=_blank style='color:#2F92EE;'>#前哨淋巴结活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32579, encryptionId=9bd2325e9f7, topicName=前哨淋巴结活检)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=979a25868441, createdName=dlwang_26703135, createdTime=Wed Mar 07 12:43:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2011308, encodeId=d27620113081b, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Mon Apr 30 23:43:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1278014, encodeId=ea6312e80148b, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1292988, encodeId=1aa412929885e, content=<a href='/topic/show?id=df626600877' target=_blank style='color:#2F92EE;'>#淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66008, encryptionId=df626600877, topicName=淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6cc1239, createdName=sodoo, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1534832, encodeId=a3b0153483291, content=<a href='/topic/show?id=47ee325e539' target=_blank style='color:#2F92EE;'>#前哨淋巴结#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32575, encryptionId=47ee325e539, topicName=前哨淋巴结)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a89e12549488, createdName=by2013, createdTime=Sun Jun 25 07:43:00 CST 2017, time=2017-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=214434, encodeId=e5c6214434af, content=学习了受益匪浅。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLDicHg2ldsSNmib46PmdzpO7CQEmPjuULp1v45zPWwMYhrnXgvl3OtmUCZSQfgITWn96X9moL94nUGA/0, createdBy=28072041016, createdName=131****1460, createdTime=Fri Jun 23 17:48:54 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2017-06-23 131****1460

    学习了受益匪浅。

    0

相关资讯

Cardiology:川崎病相关的咽后淋巴结免疫细胞的不同分布

咽后的病变通常和川崎病相关(KD)。一个4岁大的男性刚开始呈现出扁桃体周围和咽后的脓肿病变。扁桃腺外科手术的治疗避免了纵隔脓肿的风险,但是他在手术后仍旧完成了KD诊断规则。这促使了研究人员对KD扁桃体进行组织学的研究。研究人员对KD扁桃体样品的组织学病理与从4名慢性扁桃体炎患者并且通过免疫染色确定与KD无关进行了比较。 研究发现,KD扁桃体炎在扁桃体周围肌肉层表现出小的淋巴滤泡和中性粒细

Sci Rep:淋巴结转移的淋巴结外软组织转移可以影响前列腺癌复发

淋巴结转移中的外软组织转移通过淋巴结囊进入淋巴结脂肪组织,从而参与了肿瘤细胞的扩张。最近,这个形态特性表明可以作为各种癌症类型的重要预后因子,但是它在前列腺癌中的角色仍旧不清楚。最近,有研究人员鉴定了其在前列腺癌中的角色,并首次进行了前列腺组织的元分析,并与外科手术治疗的预后参数、淋巴结阳性前列腺病人包括ENE+和ENE-进行了比较。研究人员利用风险比(RRs)来总结死亡或者复发数,并利用危险比(

SCI REP:风险模型预测乳腺浸润性导管癌患者腋窝淋巴结转移的效果!

由此可见,研究中针对腋窝淋巴结转移建立的风险模型可能易化可乳腺浸润性导管癌患者后续的治疗计划和管理。

Sci Rep:利用微卫星分析技术认识肾血管平滑肌脂肪瘤的起源与局部淋巴结的参与

涉及局部淋巴结(LN)的肾血管平滑肌脂肪瘤(AML)能够引起转移问题和多中心起源的问题,并且它们的组织学特征类似。基因组不稳定性是癌症的一个普遍特性。最近,因此研究人员假设个体病人的肿瘤的独立出现应该具有可以检测的基因组变化,从而促进对肿瘤谱系和相关性的区分和认识。研究人员将12名诊断为淋巴结结点相关的肾血管平滑肌脂肪瘤患者作为研究群体,并且这些患者来自中国西部。研究人员利用6个微卫星标记,通过P

八成鼻咽癌患者伴有颈部肿块,淋巴结发炎须警惕

全球鼻咽癌患者约有80%都是来自中国。在鼻咽癌患者中,又有60%~80%的患者最初表现为颈部肿块。记者从3月18日举办的第八届全国鼻咽癌学术大会上获悉,目前国内鼻咽癌早期患者5年生存率达90%以上。放疗作为治疗鼻咽癌的最常用手段,其疗效和副作用之间权衡向来是医生和患者共同关注的焦点。在中国,鼻咽癌发病率由南到北逐渐降低,以广东省发病率最高,曾一度被叫做“广东瘤”。其原因很复杂,与多种因素有关,如人

干货:影响结肠癌淋巴结数量的非手术因素

高质量手术和病理分析是确保结肠癌淋巴结数量的最重要因素,不过还有很多因素都可能影响淋巴结数量,如老年、肥胖、男性、种族、社会经济地位等,下面一起来看看这些因素对结肠癌淋巴结数量会产生什么样的影响。增加数量的淋巴结(LN)能改善结肠癌患者生存,也是决定术后是否接受辅助化疗的基础。1990年首次提出结肠癌手术至少要切除12LN,越多淋巴结切除,肿瘤越有可能是淋巴结阳性,如果切除LN很少,则会低估肿